AstraZeneca (AZN) Tops Q3 EPS by 87c; raises guidance

AstraZeneca (NASDAQ: AZN) reported Q3 EPS of $1.73, $0.87 better than the analyst estimate of $0.86. Revenue for the quarter came in at $11.49 billion versus the consensus estimate of $11.54 billion.

GUIDANCE:

FY 2023 Total Revenue excluding COVID-19 medicines now expected to increase by a low-teens percentage at CER ‒ FY 2023 Core EPS now expected to increase by a low double-digit to low-teens percentage at CER.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• AstraZeneca and YMCA of the USA Announce Landmark Partnership Aimed to Address Gaps in Cancer Care
• KKR reports over $900M in Q2 monetization income through June 24
• Next-Generation DNA Repair Therapies Open New Frontiers in Oncology